We cannot infer from these data alone whether the combinatorial effect reflects the expression of the LM332 protein driving tumour progression or are a consequence of shared dysregulation, but these findings suggest that adding LAMA3 to existing biomarkers may improve their functionality. The gene discussed is LAMA3; the disease is neoplasm.